



UT20 Rec'd PCT/PTO 29 AUG 2003

PCT 8

Please type a plus sign (+) inside this box → ☐PTO/SB/21 (6-98)
Approved for use through 09/30/2000. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.


TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	10/088,257	
	Filing Date	MARCH 15, 2002	
	First Named Inventor	FRANCOIS BERTELLI	
	Group Art Unit		
	Examiner Name		
Total Number of Pages in This Submission		Attorney Docket Number	A0000179/2-01-EJB

ENCLOSURES (check all that apply)		
<input checked="" type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Assignment Papers (for an Application)	<input type="checkbox"/> After Allowance Communication to Group
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment / Response	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition Routing Slip (PTO/SB/69) and Accompanying Petition	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input checked="" type="checkbox"/> Additional Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	--Copies of References cited in IDS
<input checked="" type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Small Entity Statement	--Return postcard
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> Request for Refund	--Authorization debit/credit charge account 23-0455
<input type="checkbox"/> Response to Missing Parts/Incomplete Application	Remarks	
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual name	Eric J. Baude Reg. No. 47,413
Signature	
Date	8/25/03

CERTIFICATE OF MAILING			
I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, PO Box 1450, Alexandria, VA 22313 on this date: 8/25/03			
Typed or printed name	Inja Cho		
Signature		Date	8/25/03

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, VA 22313



1600
1632

Please type a plus sign (+) inside this box → ☐

PTO/SB/21 (6-98)
Approved for use through 09/30/2000. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM <i>(to be used for all correspondence after initial filing)</i>	Application Number	10/088,257	
	Filing Date	March 15, 2002	
	First Named Inventor	Francois Bertelli	
	Group Art Unit		
	Examiner Name		
Total Number of Pages in This Submission	527	Attorney Docket Number	A0000179/2-66-MG

ENCLOSURES (check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment / Response <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/ Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Assignment Papers (for an Application) <input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition Routing Slip (PTO/SB/69) and Accompanying Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Small Entity Statement <input type="checkbox"/> Request for Refund	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Additional Enclosure(s) (please identify below): Return Postcard
<div>Remarks</div> <div>RECEIVED AUG 26 2002 TECH CENTER 1600/2900</div>		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual name	Mehdi Ganjeizadeh
Signature	
Date	8/15/02

CERTIFICATE OF MAILING			
I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on this date: 8/15/02			
Typed or printed name	Cindy Malocha	Date	8/15/02
Signature			

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

FEE TRANSMITTAL for FY 2003

Effective 01/01/2003. Patent fees are subject to annual revision.

☐ Applicant claims small entity status. See 37 CFR 1.27

TOTAL AMOUNT OF PAYMENT (\$) 180.00

Complete if Known

Application Number	10/088,257
Filing Date	MARCH 15, 2002
First Named Inventor	FRANCOIS BERTELLI
Examiner Name	
Art Unit	
Attorney Docket No.	A0000179/2-01-EJB

METHOD OF PAYMENT (check all that apply)

☐ Check ☐ Credit card ☐ Money Order ☐ Other ☐ None

☒ Deposit Account:

Deposit Account Number
Deposit Account Name

23-0455

Warner-Lambert Company

The Commissioner is authorized to: (check all that apply)

☒ Charge fee(s) indicated below ☒ Credit any overpayments

☒ Charge any additional fee(s) during the pendency of this application

☐ Charge fee(s) indicated below, except for the filing fee to the above-identified deposit account.

FEE CALCULATION

1. BASIC FILING FEE

Large Entity		Small Entity		Fee Description	Fee Paid
Fee Code	Fee (\$)	Fee Code	Fee (\$)		
1001	750	2001	375	Utility filing fee	
1002	330	2002	165	Design filing fee	
1003	520	2003	260	Plant filing fee	
1004	750	2004	375	Reissue filing fee	
1005	160	2005	80	Provisional filing fee	

SUBTOTAL (1) (\$) 0.00

2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE

		Extra Claims		Fee from below		Fee Paid
Total Claims	<input type="text"/>	-20** =	<input type="text"/>	X	<input type="text"/>	= <input type="text"/>
Independent Claims	<input type="text"/>	- 3** =	<input type="text"/>	X	<input type="text"/>	= <input type="text"/>
Multiple Dependent	<input type="text"/>					= <input type="text"/>

Large Entity		Small Entity		Fee Description	Fee Paid
Fee Code	Fee (\$)	Fee Code	Fee (\$)		
1202	18	2202	9	Claims in excess of 20	
1201	84	2201	42	Independent claims in excess of 3	
1203	280	2203	140	Multiple dependent claim, if not paid	
1204	84	2204	42	** Reissue independent claims over original patent	
1205	18	2205	9	** Reissue claims in excess of 20 and over original patent	

SUBTOTAL (2) (\$) 0.00

*or number previously paid, if greater; For Reissues, see above

FEE CALCULATION (continued)

3. ADDITIONAL FEES

Large Entity		Small Entity		Fee Description	Fee Paid
Fee Code	Fee (\$)	Fee Code	Fee (\$)		
1051	130	2051	65	Surcharge - late filing fee or oath	
1052	50	2052	25	Surcharge - late provisional filing fee or cover sheet	
1053	130	1053	130	Non-English specification	
1812	2,520	1812	2,520	For filing a request for <i>ex parte</i> reexamination	
1804	920*	1804	920*	Requesting publication of SIR prior to Examiner action	
1805	1,840*	1805	1,840*	Requesting publication of SIR after Examiner action	
1251	110	2251	55	Extension for reply within first month	
1252	410	2252	205	Extension for reply within second month	
1253	930	2253	465	Extension for reply within third month	
1254	1,450	2254	725	Extension for reply within fourth month	
1255	1,970	2255	985	Extension for reply within fifth month	
1401	320	2401	160	Notice of Appeal	
1402	320	2402	160	Filing a brief in support of an appeal	
1403	280	2403	140	Request for oral hearing	
1451	1,510	1451	1,510	Petition to institute a public use proceeding	
1452	110	2452	55	Petition to revive - unavoidable	
1453	1,300	2453	650	Petition to revive - unintentional	
1501	1,300	2501	650	Utility issue fee (or reissue)	
1502	470	2502	235	Design issue fee	
1503	630	2503	315	Plant issue fee	
1460	130	1460	130	Petitions to the Commissioner	
1807	50	1807	50	Processing fee under 37 CFR 1.17(q)	
1806	180	1806	180	Submission of Information Disclosure Stmt	180.00
8021	40	8021	40	Recording each patent assignment per property (times number of properties)	
1809	750	2809	375	Filing a submission after final rejection (37 CFR 1.129(a))	
1810	750	2810	375	For each additional invention to be examined (37 CFR 1.129(b))	
1801	750	2801	375	Request for Continued Examination (RCE)	
1802	900	1802	900	Request for expedited examination of a design application	

Other fee (specify)

*Reduced by Basic Filing Fee Paid

SUBTOTAL (3) (\$) 180.00

SUBMITTED BY

Name (Print/Type) Eric J. Baude

Signature

Eric J. Baude

Registration No. 47,413
(Attorney/Agent)

(Complete if applicable)

Telephone 734 622-2095

Date 8/25/2003

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

This collection of information is required by 37 CFR 1.17 and 1.27. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, VA 22313

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/090,827 ✓	03/06/2002 ✓	Francois Bertelli	A0000179-CI-66-MG	6882

7590

02/26/2003

Mehdi Ganjeizadeh
Warner-Lambert Company
2800 Plymouth Road
Ann Arbor, MI 48105

RECEIVED

MAR 04 2003

AA PATENT DEPT

EXAMINER

WILDER, CYNTHIA B

ART UNIT

PAPER NUMBER

1637

DATE MAILED: 02/26/2003

Please find below and/or attached an Office communication concerning this application or proceeding.

Docketed	
DATE	03-26-03
OR	01-20-03 - ESB
BY:	FGB CHECKED BY:

Docketed	
DATE	03-26-03
FOR	01-20-03 - ESB
BY:	FGB CHECKED BY:



Office Action Summary

Application No.

10/090,827

Applicant(s)

BERTELLI et al.

Examiner

Cynthia B Wilder

Art Unit

1637



-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136 (a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on Aug 23, 2002
- 2a) ☐ This action is FINAL. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11; 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-5 is/are pending in the application.
- 4a) Of the above, claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 1-5 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claims _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
- 11) ☐ The proposed drawing correction filed on _____ is: a) ☐ approved b) ☐ disapproved by the Examiner.
If approved, corrected drawings are required in reply to this Office action.
- 12) ☐ The oath or declaration is objected to by the Examiner.

Priority under 35 U.S.C. §§ 119 and 120

- 13) ☐ Acknowledgement is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
a) ☐ All b) ☐ Some* c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. _____
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
*See the attached detailed Office action for a list of the certified copies not received.
- 14) ☐ Acknowledgement is made of a claim for domestic priority under 35 U.S.C. § 119(e).
a) ☐ The translation of the foreign language provisional application has been received.
- 15) ☒ Acknowledgement is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.

Attachment(s)

- 1) ☒ Notice of References Cited (PTO-892) 4) ☐ Interview Summary (PTO-413) Paper No(s). _____
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948) 5) ☐ Notice of Informal Patent Application (PTO-152)
- 3) ☒ Information Disclosure Statement(s) (PTO-1449) Paper No(s). 6 6) ☐ Other:

Art Unit: 1637

DETAILED ACTION

Specification

1. The specification is objected to because of the following informalities:
 - (a) The sequence identifier recited as "SEQ ID No" at pages 3, 4, 7, 16-18, 20, 21, 24, 26 and 29 and the sequence identifier recited as "SEQ ID N^o" at page 6 is improper. It is suggested changing "SEQ ID No" and "SEQ ID N^o" to "SEQ ID NO:" (See MPEP 2422.03).
Appropriate correction is required.

Claim Rejections - 35 USC § 102(a)

2. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless --

(a) the invention was known or used by others in this country, or patented or described in a printed publication in this or a foreign country, before the invention thereof by the Applicant for a patent.

3. Claims 1, 3, 4, and 5 are rejected under 35 U.S.C. 102(a) as being anticipated by Brown et al. and Gee et al. (*Journal of Biological Chemistry*, Vol. 273, No. 39, pp 25458-465, September 25, 1998). Regarding claims 1, Brown and Gee teach a method for screening of a ligand which binds a cerebral cortical voltage-dependent calcium channel $\alpha_2\delta$ -1 subunit, the method comprising the steps of: contacting a secreted soluble recombinant calcium channel $\alpha_2\delta$ -1 subunit polypeptide with a ligand of interest and a labeled compound which binds the $\alpha_2\delta$ -1 subunit page 25460, col. 1, lines 2-7, page 25462, col. 2, lines 6-13); and measuring the level of binding of the labeled compound to

Art Unit: 1637

the $\alpha_2\delta-1$ subunit (Abstract and page 25461, subsection "Miscellaneous Methods" entire paragraph. See also Fig. 2 and legend, page 26462.) Therefore, the reference of Brown and Gee meets all the claimed limitation of claim 1.

4. Regarding claims 3-5, Brown and Gee teach a method according to claim 1 and further teach a primary sequence of the porcine cerebral cortical voltage-dependent calcium channel $\alpha_2\delta-1$ subunit cDNA (Figure 1, page 25459) comprising sequences that are identical to the sequences of SEQ ID NOS: 6-9. Brown and Gee additionally teach mutant forms of the cDNA sequence which resulted in secreted soluble recombinant calcium channel $\alpha_2\delta-1$ subunits (see Figure 2, page 25462). Therefore, the reference of Brown and Gee meets all of the claimed limitations of claims 3-5.

Claim Rejections - 35 USC § 103(a)

5. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) a patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

6. This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and

Art Unit: 1637

invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(f) or (g) prior art under 35 U.S.C. 103(a).

7. Claim 2 is rejected under 35 U.S.C. 103(a) as being unpatentable over Brown and Gee as applied to claims 1, 3-5 above and further in view of Holland et al. (Analytical Biochemistry, November 1994). Regarding claim 2, Brown and Gee teach a method of screening of a ligand which bind the cerebral cortical voltage-dependent calcium channel $\alpha_2\delta$ -1 subunit comprising the steps of contacting a secreted soluble recombinant calcium channel $\alpha_2\delta$ -1 subunit polypeptide with a ligand of interest; and a labeled compound which binds the $\alpha_2\delta$ -1 subunit; and measuring the level of binding of the labeled compound to the $\alpha_2\delta$ -1 subunit.

The method of screening of Brown and Gee differs from that of the claim invention in that the reference does not expressly teach wherein the step of contacting and said binding is in a well of a flashplate.

Holland et al. teach a screening method of ligands using a flashplate assay wherein the contacting and binding is in the wells of a flashplate (see abstract). Holland et al. teach that the key feature of the flashplate binding assay is its simplicity. Holland et al. states that in essence, it comprises the addition of the radioligand and test compound, incubation and measurement and is convenient for screening compounds interacting at a receptor or quantitative receptor binding studies (page 517, last four lines bridging page 518, line 1). Holland further adds that no separation or washing steps are involved and this simplicity makes the assay more amenable to automation and

Art Unit: 1637

thus allows for a more robust assay. (page 517, col. 2, third paragraph; Discussion). Therefore, it would have been *prima facie* obvious to one of ordinary skill in the art at the time the invention was made to have been motivated to have modified the ligand screening method of Brown and Gee by incorporating a flashplate assay as disclosed by Holland et al. One of ordinary skill in the art would have been motivated to do so for numerous advantages taught by Holland et al. that a flashplate assay is more simpler, more convenient and more robust for screening compounds interacting at a receptor or quantitative receptor binding studies and is more amendable to automation.

Conclusion


8. No claims are allowed.
9. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Examiner Cynthia Wilder whose telephone number is (703) 305-1680. The examiner can normally be reached on Monday through Thursday from 9:30 am to 6:30 pm and on Friday from 9:30 am to 1:30 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Benzion, can be reached at (703) 308-1119. The official fax phone number for the Group is (703) 308-4242. The unofficial fax number is (703) 308-8724.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed the Group's receptionist whose telephone number is (703) 308-0196.

Art Unit: 1637


cbw
February 24, 2003

A handwritten signature in cursive script that reads "Cynthia B. Wilder".

Cynthia B. Wilder, Ph.D.
Patent Examiner
Art Unit 1637

INFORMATION DISCLOSURE C

(Use several sheets if necessary)



Docket Number (Optional)

A0000179

Application Number

09/397,549

Applicant(s)

F. BERTELLI, ET AL.

Filing Date

16 SEPTEMBER 1999

Group Art Unit

U.S. PAT. 10 090027



U.S. PATENT DOCUMENTS

EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
		5,846,757	12/08/1998	HARPOLD, ET AL.	435	29	
		5,429,921	07/04/1995	HARPOLD, ET AL.	435	4	

COPY

FOREIGN PATENT DOCUMENTS

REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
						YES	NO
CW	93/04083	03/04/1993	WO			✓	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

CW	GEE, N.S., ET AL., THE JOURNAL OF BIOLOGICAL CHEMISTRY, "THE NOVEL ANTICONVULSANT DRUG, GABAPENTIN (NEURONTIN), BINDS TO THE ALPHA2DELTA SUBUNIT OF A CALCIUM CHANNEL, 1996, VOL. 271:10, PP. 5768-5776.
CW	BROWN, J.P., ET AL., THE JOURNAL OF BIOLOGICAL CHEMISTRY, "CLONING AND DELETION MUTAGENESIS OF THE ALPHA2DELTA CALCIUM CHANNEL SUBUNIT FROM PORCINE CEREBRAL CORTEX", 1998, VOL. 273:39, PP. 25458-25465

EXAMINER

Cynthia Wilder

DATE CONSIDERED

2/21/03

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

References can be found in parent application 09/397,549.

EXPRESS MAIL NO. E1054450643 US
A0000179-C1-66-MG

INFORMATION DISCLOSURE C

(Use several sheets if necessary)

29 2003

Docket Number (optional)

A0000179

Application Number

09/397,549

Applicant(s)

F. BERTELLI, ET AL.

Filing Date

16 SEPTEMBER 1999

Group Art Unit

EXAMINER

INITIAL

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)

KOWALSKI, M.T., ET AL. BIOCHEMICAL SOCIETY TRANSACTIONS. "EFFECTS OF ANTI-CALCIUM CHANNEL A2-SUBUNIT ANTIBODIES ON CALCIUM FLUX AND 1,4-DIHYDROPYRIDINE BINDING" 1990, P. 890

GURNETT, C.A., ET AL. THE J. OF BIOLOGICAL CHEMISTRY, "EXTRACELLULAR INTERACTION OF THE VOLTAGE-DEPENDENT CA2+ CHANNEL ALPHA2 DELTA AND ALPHA1 SUBUNITS", 1997, 272:29 PP 18508-18512

GURNETT, C.A., ET AL. NEURON, "DUAL FUNCTION OF THE VOLTAGE-DEPENDENT CA2+ CHANNEL ALPHA2DELTA SUBUNIT IN CURRENT STIMULATION AND SUBUNIT INTERACTION" 1996, VOL. 16, PP 431-440

FELIX, R., ET AL., J. OF NEUROSCIENCE, "DISSECTION OF FUNCTIONAL DOMAINS OF THE VOLTAGE-DEPENDENT CA2+ CHANNEL ALPHA2DELTA SUBUNIT", 1997, VOL. 17:18, PP. 6884-6891

FIELD, M.J., ET AL., BRITISH JOURNAL OF PHARMACOLOGY, "GABAPENTIN (NEURONTIN) AND S-(+)-3-ISOBUTYL GABA REPRESENT A NOVEL CLASS OF SELECTIVE ANTIHYPERALGESIC AGENTS", 1997, VOL. 121, PP. 1513-1522

KLUGBAUER, N., ET AL., THE JOURNAL OF NEUROSCIENCE, "MOLECULAR DIVERSITY OF THE CALCIUM CHANNEL ALPHA2DELTA SUBUNIT", 1999, VOL. 19:2, PP. 684-691

TOKUMARU, H., ET AL., EUROPEAN JOURNAL OF PHARMACOLOGY-MOLECULAR PHARMACOLOGY SECTION, "PURIFICATION OF THE CARDIAC 1,4-DIHYDROPYRIDINE RECEPTOR USING IMMUNOAFFINITY CHROMATOGRAPHY WITH A MONOCLONAL ANTIBODY AGAINST THE ALPHA2DELTA SUBUNIT OF THE SKELETAL MUSCLE DIHYDROPYRIDINE RECEPTOR" 1992, VOL. 227, PP. 363-370.

HILL, D.R., ET AL., EUROPEAN JOURNAL OF PHARMACOLOGY-MOLECULAR PHARMACOLOGY SECTION, "LOCALIZATION OF [3H]GABAPENTIN TO A NOVEL SITE IN RAT BRAIN: AUTORADIOGRAPHIC STUDIES", 1993, VOL. 244, PP. 303-309

DISSANAYAKE, V.U.K., ET AL., BRITISH JOURNAL OF PHARMACOLOGY, "SPERMINE MODULATION OF SPECIFIC [3H]-GABAPENTIN BINDING TO THE DETERGENT-SOLUBILIZED PORCINE CEREBRAL CORTEX ALPHA2DELTA CALCIUM CHANNEL SUBUNIT" 1997, VOL. 120, PP. 833-840

BRICKLEY, K., ET AL., FEBS LETTERS, "USE OF SITE-DIRECTED ANTIBODIES TO PROBE THE TOPOGRAPHY OF THE ALPHA2 SUBUNIT OF VOLTAGE-GATED CA2+ CHANNELS", 1995, VOL. 364, PP. 129-133

TAYLOR, C.P., ET AL., EPILEPSY RESEARCH, "POTENT AND STEREOSPECIFIC ANTICONVULSANT ACTIVITY OF 3-ISOBUTYL GABA RELATES TO IN VITRO BINDING AT A NOVEL SITE LABELED BY TRITIATED GABAPENTIN, 1993, VOL. 14, PP. 11-15

THURLOW, R.J., ET AL., EUROPEAN JOURNAL OF PHARMACOLOGY-MOLECULAR PHARMACOLOGY SECTION, "[3H]GABAPENTIN MAY LABEL A SYSTEM-L-LIKE NEUTRAL AMINO ACID CARRIER IN BRAIN", 1993, VOL. 247, PP. 341-345

SUMAN-CHAUHAN, N., ET AL., EUROPEAN JOURNAL OF PHARMACOLOGY-MOLECULAR PHARMACOLOGY SECTION, "CHARACTERISATION OF [3H]GABAPENTIN BINDING TO A NOVEL SITE IN RAT BRAIN: HOMOGENATE BINDING STUDIES", 1993, VOL. 244, PP. 293-301

ELLIS, S.B., ET AL., SCIENCE, "SEQUENCE AND EXPRESSION OF MRNAS ENCODING THE ALPHA1 AND ALPHA2 SUBUNIT OF A DHP-SENSITIVE CALCIUM CHANNEL", 1988, VOL. 241, PP. 1661-1664

DEJONGH, K.S., THE JOURNAL OF BIOLOGICAL CHEMISTRY, "SUBUNITS OF PURIFIED CALCIUM CHANNELS", 1990, VOL. 265, PP. 14738-14741.

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


POSB/REV04

SHEET 2 OF 3

References can be found in Parent application 09/397,549

INFORMATION DISCLOSURE

(Use several sheets if necessary)



Docket Number (Optional)

A0000179

Application Number

09/397,549

Applicant(s)

F. BERTELLI, ET AL.

Filing Date

16 SEPTEMBER 1999

Group Art Unit

*EXAMINER
INITIAL

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

CW

JAY, S.D., ET AL., THE JOURNAL OF BIOLOGICAL CHEMISTRY, "STRUCTURAL CHARACTERIZATION OF THE DIHYDROPYRIDINE-SENSITIVE CALCIUM CHANNEL ALPHA2-SUBUNIT AND THE ASSOCIATED DELTA PEPTIDES", 1991, VOL 266, PP. 3287-3293

CW

WISER, O., ET AL., FEBS LETTERS, "THE ALPHA2/DELTA SUBUNIT OF VOLTAGE SENSITIVE CA2+ CHANNELS IS A SINGLE TRANSMEMBRANE EXTRACELLULAR PROTEIN WHICH IS INVOLVED IN REGULATED SECRETION", 1996, VOL 379, PP. 15-20.

CW

BROWN, J.P., ET AL., REV. CONTEMP. PHARMACOTHER, "MECHANISMS OF ACTION OF GABAPENTIN", 1996, VOL 7, PP. 203-214

CW

BROWN, J.P., ET AL., ANALYTICAL BIOCHEMISTRY, "ISOLATION OF THE [3H]GABAPENTIN-BINDING PROTEIN/ALPHA2DELTA CA2+ CHANNEL SUBUNIT FROM PORCINE BRAIN: DEVELOPMENT OF A RADIOLIGAND BINDING ASSAY FOR ALPHA2DELTA SUBUNITS USING [3H]LEUCINE", 1998, VOL 255, PP. 236-243

EXAMINER

Cynthia Wilder

DATE CONSIDERED

2/21/03

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

References can be found in 09/397,549

POSB/REV04

SHEET 3

OF 3

SERIAL NO.
10/090,827

**COPY OF PAPERS
ORIGINALLY FILED**

(Use several sheets if necessary)

FILING DATE
March 6, 2002

GROUP
1637

U.S. PATENT DOCUMENTS

U.S. PATENT DOCUMENTS													
EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS															TRANSLATION	
		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUBCLASS	YES	NO		
(Ch)		0	0	2	0	4	5	0	13.04.00	WO				x		

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc)

Handwritten: *aw*

Holland et al., "A Nonseparation Microplate Receptor Binding Assay", Analytical Biochemistry, Vol. 222, 1994, pages 516-518

RECEIVED
AUG 26 2002
TECH CENTER 1600:2900

EXAMINER

DATE CONSIDERED ~~_____~~

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ANY COPIES OF DOCUMENTS LISTED ON THIS FORM PTO-1449 SHOULD HAVE CERTAIN INFORMATION PLACED ALONG THE LEFT SIDE OF THE DOCUMENT. INFORMATION SUCH AS DOCKET NUMBER, FILING DATE, SERIAL NUMBER, ART UNIT, ETC.

Notice of References Cited

AUG 29 2003

PATENT & TRADEMARK

Application/Control No.
10/090,827

Applicant(s)/Patent Under Reexam
BERTELLI et al.

Examiner
Cynthia B Wilder

Art Unit
1637

Page 1 of 1

U.S. PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY ¹	Name	Classification ²
	A				
	B				
	C				
	D				
	E				
	F				
	G				
	H				
	I				
	J				
	K				
	L				
	M				

FOREIGN PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY ¹	Country	Name	Classification ²
	N					
	O					
	P					
	Q					
	R					
	S					
	T					

NON-PATENT DOCUMENTS

*		Include, as applicable: Author, Title, Date, Publisher, Edition or Volume, Pertinent Pages
x	U	Holland et al. A nonseparation microplate receptor binding Assay. Analytical Biochemistry, Vol. 222, pages 516-518.
x	V	Brown and Gee. Cloning and Deletion Mutagenesis of the Alpha 2 beta calcium channel subunit from porcine cerebral cortex. Vol 273, No. 39, pages 25458-25465, September 1998.
	W	
	X	

^{*} A copy of this reference is not being furnished with this Office action. See MPEP § 707.05(a).

¹ Dates in MM-YYYY format are publication dates.

² Classifications may be U.S. or foreign.